Sustol Approval History
- FDA approved: Yes (First approved August 9th, 2016)
- Brand name: Sustol
- Generic name: granisetron
- Company: Heron Therapeutics, Inc.
- Treatment for: Nausea/Vomiting, Chemotherapy Induced
Sustol (granisetron) is a long-acting 5-HT3 antagonist indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens.
Granisetron was first approved by the FDA in 1993 and is available generically in oral tablet and injection formulations.
Sustol injection is administered by a healthcare practitioner subcutaneously over 20 to 30 seconds. It is given in combination with dexamethasone at least 30 minutes before the start of chemotherapy, on the first day of the chemotherapy cycle. The long acting formulation is intended to last at least five days, covering both the acute and delayed phases of CINV.
Common side effects include injection site reactions (infections, bruising, pain, tenderness), constipation, fatigue, headache, diarrhea, abdominal pain, insomnia, dyspepsia, dizziness, asthenia, and gastroesophageal reflux.
Development History and FDA Approval Process for Sustol
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.